Scorpion Capital Tweets "Minutes ago, the FDA replied to our Citizen Petition requesting withdrawal of approval of Harmony Biosciences' drug Wakix. We are pleased that the FDA Is taking our concerns seriously, and view the interim response as ominous for Harmony"
Portfolio Pulse from Benzinga Newsdesk
Scorpion Capital has received an interim response from the FDA regarding their petition to withdraw approval of Harmony Biosciences' drug Wakix. The FDA has stated that the petition raises complex issues requiring extensive review and analysis. The final decision is expected within two weeks.
September 21, 2023 | 7:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harmony Biosciences' drug Wakix is under scrutiny by the FDA due to a petition filed by Scorpion Capital. The FDA's interim response indicates a thorough review, which could potentially lead to withdrawal of the drug's approval.
The FDA's response to Scorpion Capital's petition indicates that they are taking the concerns seriously. This could potentially lead to the withdrawal of approval for Harmony Biosciences' drug Wakix, which would have a significant negative impact on the company's stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100